logo

For the Inventor, By the Inventor

Vienna, Austria

Christian Stratowa

This inventor holds 14 USPTO granted patents. Top assignees: Amgen Inc., Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Gmbh. Active years: 1993-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christian Stratowa. Retrieved from https://idiyas.com/inventor/christian-stratowa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14

% Patents Active = 85.7

Average Co-Inventor Count = 5.1

ph-index = 6

Forward Citations = 110(Granted Patents)


Location History:

  • Wien, AT (1996)
  • Vienna, AT (1993 - 2007)

Company Filing History:

goldMedal7 out of 2,069 
 
Amgen Inc.
 patents
silverMedal5 out of 1,561 
 
Boehringer Ingelheim International Gmbh
 patents
bronzeMedal1 out of 306 
 
Boehringer Ingelheim Gmbh
 patents
4. 1 out of 834,453 
Other
 patents

Years Active: 1993-2007

Loading Chart...
14 patents (USPTO):Explore Patents
1. 7282483 - Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF (2007-10-16),
2. 7264944 - TNF receptors, TNF binding proteins and DNAs coding for them (2007-09-04),
3. 7238776 - TNF binding proteins (2007-07-03),
4. 6440693 - TNF receptors, TNF binding proteins and DNAS coding for them (2002-08-27),
5. 6417158 - Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF (2002-07-09),
6. 6294352 - TNF receptors, TNF binding proteins and DNAs coding for them (2001-09-25),
7. 6271346 - TNF Receptors, TNF binding proteins and DNAs coding for them (2001-08-07),
8. 6221675 - TNF receptors, TNF binding proteins and DNAs coding for them (2001-04-24),
9. 5854004 - Process for screening substances capable of modulating a (1998-12-29),
10. 5837842 - Vascular anticoagulant proteins DNA which codes them, processer for (1998-11-17),
11. 5589371 - Human manganese superoxide dismutase (hMn-SOD) (1996-12-31),
12. 5436162 - Human manganese superoxide dismutase (hMn-SOD) (1995-07-25),
13. 5260204 - Human manganese superoxide dismutase (hMn-SOD) (1993-11-09),
14. 5240847 - Human manganese superoxide dismutase (hMn-SOD) (1993-08-31),

Title: Christian Stratowa: Innovator in TNF-Binding Protein Research

Introduction

Christian Stratowa is a prominent inventor based in Vienna, Austria. He has made significant contributions to the field of biotechnology, particularly in the development of methods to ameliorate the harmful effects of tumor necrosis factor (TNF). With a total of 14 patents to his name, Stratowa's work has had a substantial impact on pharmaceutical preparations aimed at treating TNF-related conditions.

Latest Patents

Stratowa's latest patents focus on the method of ameliorating the harmful effects of TNF using a polypeptide that binds to TNF. The inventions provide DNA sequences coding for a TNF-binding protein and the TNF receptor, which constitutes the soluble domain. These DNA sequences can be utilized to prepare recombinant DNA molecules for producing TNF-binding proteins and receptors. The recombinant TNF-binding protein is essential in pharmaceutical preparations for treating conditions where TNF has detrimental effects. Furthermore, the TNF receptor or its fragments can be used to investigate substances for their interaction with the TNF receptor and their effects on TNF's biological activity.

Career Highlights

Throughout his career, Christian Stratowa has worked with notable companies in the biotechnology sector, including Amgen Inc. and Boehringer Ingelheim International GmbH. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in the field.

Collaborations

Stratowa has collaborated with esteemed colleagues such as Ingrid Maurer-Fogy and Rudolf Hauptmann. These partnerships have fostered innovation and have been instrumental in advancing research related to TNF-binding proteins.

Conclusion

Christian Stratowa's innovative work in the field of biotechnology, particularly regarding TNF-binding proteins, has led to significant advancements in pharmaceutical applications. His contributions continue to influence the development of treatments for conditions associated with TNF.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…